Immunovant will not pursue further development of IMVT-1402 for skin lupus after a trial missed its main goal, despite some favorable trends.

There is a space that too many people with lupus are forced to live in, between being considered “disabled” and being expected to function as though nothing were wrong. I know that space. Many of you ...

I recently came across an episode from the Lupus Foundation of America’s “The Expert Series” that focused on menopause and lupus. It reminded me of how important it is for us to talk about the changes ...

Disruption of a natural process called X-chromosome inactivation (XCI) in immune B-cells — occurring when one X chromosome in females is turned off during development — may directly contribute to the ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google There’s a question many of us are asked every single day: “How ...

There’s a touchy topic in the world of chronic illness that most of us have to deal with at some point: how to navigate the workplace. I’m talking about the real-life version, not the picture-perfect, ...

The U.S. Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) as an add-on treatment for adults with lupus nephritis, a form of lupus marked by kidney damage. Lupus is an autoimmune ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google When you live with a chronic illness like lupus, you eventually ...

What would you do if you were stuck in the grocery store parking lot, crippled by locked joints? Imagine your hands and wrists frozen after parking the car, with toes cramped, shifted apart, and bent.

The U.S. Food and Drug Administration (FDA) has agreed to review an application by Roche seeking approval of obinutuzumab for the treatment of lupus nephritis, a lupus complication marked by kidney ...

Treatment with dapirolizumab pegol is better than a placebo at controlling disease activity in people with systemic lupus erythematosus (SLE), according to new results from a Phase 3 clinical trial.